RAS mutations as predictive biomarkers in clinical management of metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 15, Issue 2, 2016, Pages 95-103

  Waring, Paul ^a   Tie, Jeanne ^b   Maru, Dipen ^c   Karapetis, Christos S ^d,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d FLINDERS UNIVERSITY   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

Cetuximab; KRAS; mCRC; NRAS; Panitumumab

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; NUCLEOTIDE; OXALIPLATIN; PANITUMUMAB; RAS PROTEIN; TUMOR MARKER; KRAS PROTEIN, HUMAN; PROTEIN P21;

ANALYTIC METHOD; BIOLOGICAL ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); EXON; GENE FREQUENCY; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC IDENTIFICATION; HUMAN; LIMIT OF DETECTION; MANAGED CARE; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; MOLECULAR CLONING; MONOTHERAPY; MUTATION RATE; NONHUMAN; ONCOGENE RAS; OUTCOME ASSESSMENT; PATHOGENICITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYCLONAL ACTIVATION; PREDICTIVE VALUE; PROGNOSTIC ASSESSMENT; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR NECROSIS; COLORECTAL TUMOR; GENETICS; MUTATION; PROGNOSIS;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; HUMANS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84959549216     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2015.10.006     Document Type: Review

References (88)

1. F. Bray, J.-S. Ren, E. Masuyer, and J. Ferlay Global estimates of cancer prevalence for 27 sites in the adult population in 2008 Int J Cancer 132 2012 1133 1145
2. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact-sheets-population.aspx. Accessed July 15, 2015.
3. J.A. McCubrey, L.S. Steelman, W.H. Chappell, and et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochim Biophys Acta 1773 2007 1263 1284
4. I.A. Prior, P.D. Lewis, and C. Mattos A comprehensive survey of Ras mutations in cancer Cancer Res 72 2012 2457 2467
5. S. Schubbert, K. Shannon, and G. Bollag Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 2007 295 308
6. V.K. Morris, F.A. Lucas, M.J. Overman, and et al. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer Ann Oncol 25 2014 2008 2014
7. J.L. Bos, E.R. Fearon, S.R. Hamilton, and et al. Prevalence of ras gene mutations in human colorectal cancers Nature 327 1987 293 297
8. C.P. Vaughn, S.D. Zobell, L.V. Furtado, C.L. Baker, and W.S. Samowitz Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer Genes Chromosomes Cancer 50 2011 307 312
9. E. Van Cutsem, A. Cervantes, B. Nordlinger, D. Arnold ESMO Guidelines Working Group Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 25 suppl 3 2014 iii1 9
10. N. Knijn, L.J. Mekenkamp, M. Klomp, and et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients Br J Cancer 104 2011 1020 1026
11. D. Santini, F. Loupakis, B. Vincenzi, and et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice Oncologist 13 2008 1270 1275
12. S. Artale, A. Sartore-Bianchi, S.M. Veronese, and et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer J Clin Oncol 26 2008 4217 4219
13. H.J. Andreyev, A.R. Norman, D. Cunningham, J.R. Oates, and P.A. Clarke Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study J Natl Cancer Inst 90 1998 675 684
14. G. Hutchins, K. Southward, K. Handley, and et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer J Clin Oncol 29 2011 1261 1270
15. S. Ogino, J.A. Meyerhardt, N. Irahara, and et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 Clin Cancer Res 15 2009 7322 7329
16. A.D. Roth, S. Tejpar, M. Delorenzi, and et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 28 2010 466 474
17. T.S. Maughan, R.A. Adams, C.G. Smith, and et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 2011 2103 2114
18. S.D. Richman, M.T. Seymour, P. Chambers, and et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial J Clin Oncol 27 2009 5931 5937
19. J. Tol, J.R. Dijkstra, M. Klomp, and et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab Eur J Cancer 46 2010 1997 2009
20. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, and et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
21. T.J. Price, J.E. Hardingham, C.K. Lee, and et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer J Clin Oncol 29 2011 2675 2682
22. J. Tie, L. Lipton, J. Desai, and et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer Clin Cancer Res 17 2011 1122 1130
23. G. Karagkounis, M.S. Torbenson, H.D. Daniel, and et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases Cancer 119 2013 4137 4144
24. J.N. Vauthey, G. Zimmitti, S.E. Kopetz, and et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases Ann Surg 258 2013 619 626
25. E. Van Cutsem, M. Peeters, S. Siena, and et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664
26. J.Y. Douillard, S. Siena, J. Cassidy, and et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
27. M. Peeters, T.J. Price, A. Cervantes, and et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 2010 4706 4713
28. R.G. Amado, M. Wolf, M. Peeters, and et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
29. C.J. Allegra, J.M. Jessup, M.R. Somerfield, and et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2009 2091 2096
30. A.S. Behl, K.A. Goddard, T.J. Flottemesch, and et al. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer J Natl Cancer Inst 104 2012 1785 1795
31. M. Peeters, J.Y. Douillard, E. Van Cutsem, and et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab J Clin Oncol 31 2013 759 765
32. C.C. Chen, T.K. Er, Y.Y. Liu, and et al. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations PLoS One 8 2013 e55793
33. I. Messner, G. Cadeddu, W. Huckenbeck, and et al. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines J Cancer Res Clin Oncol 139 2013 201 209
34. S.S. Kumar, T.J. Price, O. Mohyieldin, M. Borg, A. Townsend, and J.E. Hardingham KRAS G13D mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model Gastrointest Cancer Res 7 2014 23 26
35. S. Guerrero, I. Casanova, L. Farré, A. Mazo, G. Capellà, and R. Mangues K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression Cancer Res 60 2000 6750 6756
36. W. De Roock, D.J. Jonker, F. Di Nicolantonio, and et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820
37. C. Mao, Y.F. Huang, Z.Y. Yang, D.Y. Zheng, J.Z. Chen, and J.L. Tang KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis Cancer 119 2013 714 721
38. S. Tejpar, I. Celik, M. Schlichting, U. Sartorius, C. Bokemeyer, and E. Van Cutsem Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 30 2012 3570 3577
39. M. Schirripa, S. Lonardi, C. Cremolini, and et al. Phase II study of single-agent cetuximab in KRASG13D mutant metastatic colorectal cancer (mCRC) J Clin Oncol 32 suppl 2014 abstract 3524
40. S.A. Forbes, N. Bindal, S. Bamford, and et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic Acids Res 39 2011 D945 D950
41. G. Smith, R. Bounds, H. Wolf, R.J. Steele, F.A. Carey, and C.R. Wolf Activating K-ras mutations outwith "hotspot" codons in sporadic colorectal tumours - implications for personalised cancer medicine Br J Cancer 102 2010 693 703
42. F. Molinari, L. Felicioni, M. Buscarino, and et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer Clin Cancer Res 17 2011 4901 4914
43. F. Loupakis, A. Ruzzo, C. Cremolini, and et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer Br J Cancer 101 2009 715 721
44. H.J. Lenz, D. Niedzwiecki, F. Innocenti, C.D. Blanke, and M.R. Mahoney CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): expanded ras analyses Ann Oncol 25 suppl 4 2014 abstract 501O
45. J.Y. Douillard, K.S. Oliner, S. Siena, and et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
46. L. Schwartzberg, F. Rivera, M. Karthaus, and et al. Analysis of KRAS/NRAS mutations in PEAK: a randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) J Clin Oncol 31 suppl 2013 abstract 3631
47. M. Peeters, K.S. Oliner, T.J. Price, and et al. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC) J Clin Oncol 32 suppl 2014 abstract 3568
48. M. Peeters, K.S. Oliner, A. Parker, and et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer Clin Cancer Res 19 2013 1902 1912
49. S.D. Patterson, M. Peeters, S. Siena, and et al. Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408) J Clin Oncol 31 suppl 2013 abstract 3617
50. M.T. Seymour, S.R. Brown, G. Middleton, and et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial Lancet Oncol 14 2013 749 759
51. S. Stintzing, A. Jung, L. Rossius, and et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients Eur J Cancer 49 suppl 3 2013 abstract LBA17
52. C. Bokemeyer, C.-H. Kohne, F. Ciardiello, and et al. Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab J Clin Oncol 32 suppl 2014 abstract 3505
53. F. Ciardiello, H. Lenz, and C. Kohne Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab J Clin Oncol 32 suppl 2014 abstract 3506
54. M.J. Sorich, M.D. Wiese, A. Rowland, G. Kichenadasse, R.A. McKinnon, and C.S. Karapetis Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials Ann Oncol 26 2015 13 21
55. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer Nature 487 2012 330 337
56. E. Van Cutsem, C.H. Köhne, I. Láng, and et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
57. C. Bokemeyer, I. Bondarenko, J.T. Hartmann, and et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 2011 1535 1546
58. E. Van Cutsem, H.J. Lenz, C.H. Köhne, and et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer J Clin Oncol 33 2015 692 700
59. V. Heinemann, L.F. von Weikersthal, T. Decker, and et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 2014 1065 1075
60. A.P. Venook, D. Niedzwiecki, H.-J. Lenz, and et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) J Clin Oncol 32 suppl 2014 abstract LBA3
61. L.S. Schwartzberg, F. Rivera, M. Karthaus, and et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer J Clin Oncol 32 2014 2240 2247
62. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Colon Cancer, version 2.2015. Available at: http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf. Accessed May 11, 2015.
63. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Rectal Cancer, version 2.2015. Available at: http://www.nccn.org/professionals/physician-gls/pdf/rectal.pdf. Accessed May 11, 2015.
64. M. Janakiraman, E. Vakiani, Z. Zeng, and et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer Cancer Res 70 2010 5901 5911
65. K.W. Gripp, and A.E. Lin Costello syndrome: a ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations Genet Med 14 2012 285 292
66. S. Edkins, S. O'Meara, A. Parker, and et al. Recurrent KRAS codon 146 mutations in human colorectal cancer Cancer Biol Ther 5 2006 928 932
67. F. Al-Mulla, J.J. Going, E.T. Sowden, A. Winter, I.R. Pickford, and G.D. Birnie Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality J Pathol 185 1998 130 138
68. I. Albanese, A.G. Scibetta, M. Migliavacca, and et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations Biochem Biophys Res Commun 325 2004 784 791
69. V. Kosmidou, E. Oikonomou, M. Vlassi, and et al. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications Hum Mutat 35 2014 329 340
70. F. Day, A. Muranyi, S. Singh, and et al. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer Target Oncol 10 2014 99 109
71. R. Wong, and D. Cunningham Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies J Clin Oncol 26 2008 5668 5670
72. F. Loupakis, L. Pollina, I. Stasi, and et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer J Clin Oncol 27 2009 2622 2629
73. J.M. Baas, L.L. Krens, H.J. Guchelaar, H. Morreau, and H. Gelderblom Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review Oncologist 16 2011 1239 1249
74. P. Mariani, M. Lae, A. Degeorges, and et al. Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis Anticancer Res 30 2010 4229 4235
75. E. Vakiani, M. Janakiraman, R. Shen, and et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas J Clin Oncol 30 2012 2956 2962
76. C.B. Han, F. Li, J.T. Ma, and H.W. Zou Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review Cancer Invest 30 2012 741 747
77. A. Altimari, D. de Biase, G. De Maglio, and et al. 454 Next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples Onco Targets Ther 6 2013 1057 1064
78. M.J. Higgins, D. Jelovac, E. Barnathan, and et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood Clin Cancer Res 18 2012 3462 3469
79. C. Bettegowda, M. Sausen, R.J. Leary, and et al. Detection of circulating tumor DNA in early- and late-stage human malignancies Sci Transl Med 6 2014 224ra24
80. A.R. Thierry, F. Mouliere, S. El Messaoudi, and et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Nat Med 20 2014 430 435
81. L. De Mattos-Arruda, B. Weigelt, J. Cortes, and et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle Ann Oncol 25 2014 1729 1735
82. M. Bouchahda, A. Karaboue, R. Saffroy, and et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis Cancer Chemother Pharmacol 66 2010 605 609
83. K. Balschun, J. Haag, A.K. Wenke, W. von Schonfels, N.T. Schwarz, and C. Rocken KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications J Mol Diagn 13 2011 436 445
84. T. Kimura, K. Okamoto, H. Miyamoto, and et al. Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy Oncology 82 2012 298 304
85. M. Dono, C. Massucco, S. Chiara, and et al. Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer Mol Med 18 2013 1519 1526
86. D. Tougeron, T. Lecomte, J.C. Pagès, and et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer Ann Oncol 24 2013 1267 1273
87. S. Misale, R. Yaeger, S. Hobor, and et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
88. L.A. Diaz Jr., R.T. Williams, J. Wu, and et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 2012 537 540